Caligan Partners LP - 30 Sep 2025 SCHEDULE 13G Report for Avalo Therapeutics, Inc. Common Stock, par value $0.001 per share (AVTX)

Filing Manager: Caligan Partners LP
Reporting Manager: Caligan Partners LP
Security: Avalo Therapeutics, Inc. Common Stock, par value $0.001 per share
Symbol: AVTX
Shares outstanding: 13,227,508 shares
Disclosed Ownership: 833,333 shares
Ownership: 6.3%
Form type: SCHEDULE 13G
Filing time: 14 Nov 2025, 14:31:46 UTC
Date of event: 30 Sep 2025
Next filing: 17 Feb 2026
SEC: View on sec.gov

Reporting Managers (2)

Name	Ownership	Shares Owned	sole voting power	shared voting power	Signature	Title	CIK
Caligan Partners LP	6.3%	833,333	0	833,333	/s/ David Johnson	David Johnson, Managing Partner
David Johnson	6.3%	833,333	0	833,333	/s/ David Johnson	David Johnson, Individually